AI alert system aims to slash deadly hospital blood clots
NCT ID NCT06939803
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
Hospital-acquired blood clots are a leading cause of death in U.S. hospitals. This study tests an AI tool called VTE-AI that automatically identifies patients at high risk for clots and alerts doctors if prevention hasn't been ordered. Over 2,200 patients across four hospitals will be randomly assigned to either the AI tool or the standard manual risk assessment. The goal is to see if the AI approach reduces the number of blood clots that develop during hospital stays.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI-driven clinical decision support tool (VTE-AI)
What this could lead to
If successful, this AI tool could help hospitals prevent dangerous blood clots in patients, reducing deaths and long-term complications.
What could go wrong
This is a single health system study; results may not apply elsewhere. The AI might generate too many alerts, causing alert fatigue, or fail to reduce clots significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOTHROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••